MTEX Mannatech Inc.

Mannatech’s Ambrotose Powder Boosts Cognitive Functions to Support Student Success in Time for Zhongkao and Gao Kao

Mannatech®, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, offers the innovative nutritional supplement Ambrotose® which is clinically proven to provide cognitive support for young adult functions essential to reach their potential in the classroom. This is even more critical now as success in the upcoming Zhongkao and Gao Kao are essential for future academic advancement.

According to human clinical trials published in peer reviewed journals, Ambrotose powders can positively impact brainwaves associated with attention in young adults and improve memory and alertness in middle-aged adults.

The cognitive factors of focus, attention and memory are crucial for young adult students aiming for high academic achievement.

“Clinical studies conducted by independent scientists who are experts in their fields have found that Ambrotose powder gives a helpful boost in memory, focus and attention as well as providing perceived beneficial changes in well-being,” said Dr. Rolando Maddela, MD, MPH, CCRP, Mannatech’s Director of Clinical Research and Scientific Affairs. “For young adults who are students, Ambrotose products can be a positive addition to a comprehensive approach to academic achievement. Ambrotose may also play an important role in the overall health and wellness of students, a factor that also contributes to academic success.”

Dr. Maddela suggests that as little as four grams per day of Advanced Ambrotose® powder or capsules may help support some of the factors that contribute to success in the classroom.

Mannatech is the pioneer in developing Glyconutritional technology, which includes Ambrotose powders. Ambrotose encourages cellular communication and is shown to support cognitive functions – including memory, focus and attention, as well as supporting the body’s immune and digestive systems to encourage overall health.

Some of Mannatech’s Glyconutritional products are supported by industry-standard clinical studies, including 17 human clinical trials that have been published, 12 of which were double-blind, placebo-controlled studies — the gold standard for product validation. For more on Mannatech’s rigorous scientific research, please visit MannatechScience.org.

Advanced Ambrotose is clinically tested to improve cognitive function and support the body’s immune system.

For more information about Mannatech and its products, please visit www.MeiTaiChina.com.†^

About Mannatech

Mannatech, Incorporated, offers a profound wellness experience that makes a difference in the lives of people across the world. Through its innovative Glyconutrition products, Mannatech changes lives, providing an unprecedented level of natural wellness, freedom and purpose. With more than 20 years of experience and operations in 26 markets, Mannatech is committed to transforming lives. For more information, visit MeiTaiChina.com.

Please note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

†Customers who invite other customers to the Mannatech China cross-border e-commerce site gain rewards for future product purchases or cash redemption. The e-commerce business model is not multi-level marketing or direct selling.

^Mannatech’s cross-border e-commerce model in China is a different opportunity from Mannatech’s MLM business in other markets. Our cross-border e-commerce model in China is not an MLM or direct selling business.

EN
28/02/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Mannatech Inc.

 PRESS RELEASE

Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of ...

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the “Board”) appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominat...

 PRESS RELEASE

Mannatech Reports Financial Results for Third Quarter 2024

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024. Third Quarter Highlights Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease...

 PRESS RELEASE

Mannatech Reports Financial Results for Second Quarter 2024

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease ...

 PRESS RELEASE

Mannatech Announces Appointment of James Clavijo as Chief Financial Of...

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ: LVGN), Guided Therapeutics (OTC: GTHP), Aeterna Zentaris (NASDAQ: AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical c...

 PRESS RELEASE

Mannatech Reports Financial Results for First Quarter 2024

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2024. First Quarter Highlights Net sales for the quarter ended March 31, 2024 were $29.4 million, as compared to $34.1 million for the same period in 2023, a decrease of $4.7 million, or 13.8%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $3.9 million, or 11.3%, and unfavorable foreign exchange caused a $0.8 million decrease in GAAP net sales as compar...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch